SYNACT PHARMA ApS
Credit rating
Company information
About SYNACT PHARMA ApS
SYNACT PHARMA ApS (CVR number: 34459975) is a company from RUDERSDAL. The company recorded a gross profit of -63448.4 kDKK in 2023. The operating profit was -70.9 mDKK, while net earnings were -65.4 mDKK. The profitability of the company measured by Return on Assets (ROA) was -218.8 %, which can be considered poor and Return on Equity (ROE) was -263.8 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 58.2 %, a level that can be considered to be modest. This means a balanced mix of debt and equity financing its assets—a typical operational level for many companies. SYNACT PHARMA ApS's liquidity measured by quick ratio was 2.8 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
Financial information
See financialsGross profit (kDKK)
EBIT (kDKK)
Profitability
Solidity
Key figures (kDKK)
See financials2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Volume | |||||
Net sales | |||||
Gross profit | -11 468.38 | -16 674.00 | -43 429.98 | -46 951.48 | -63 448.35 |
EBIT | -11 707.05 | -16 961.00 | -46 549.51 | -55 222.33 | -70 869.19 |
Net earnings | -9 826.31 | -14 002.00 | -41 156.63 | -49 780.30 | -65 408.93 |
Shareholders equity total | -21 827.05 | 11 358.00 | 6 649.03 | 33 994.89 | 15 585.96 |
Balance sheet total (assets) | 6 075.98 | 12 691.00 | 13 544.10 | 37 947.15 | 26 784.89 |
Net debt | 24 376.19 | -6 452.00 | -2 918.42 | -13 149.75 | -12 138.68 |
Profitability | |||||
EBIT-% | |||||
ROA | -49.0 % | -83.5 % | -354.9 % | -213.6 % | -218.8 % |
ROE | -145.8 % | -160.6 % | -457.1 % | -245.0 % | -263.8 % |
ROI | -52.4 % | -89.1 % | -517.0 % | -270.0 % | -263.7 % |
Economic value added (EVA) | -8 810.83 | -12 450.16 | -41 307.23 | -49 058.25 | -65 562.48 |
Solvency | |||||
Equity ratio | -78.2 % | 89.5 % | 49.1 % | 89.6 % | 58.2 % |
Gearing | -122.3 % | 0.0 % | |||
Relative net indebtedness % | |||||
Liquidity | |||||
Quick ratio | 0.2 | 8.3 | 1.5 | 8.6 | 2.8 |
Current ratio | 0.2 | 8.3 | 1.5 | 8.6 | 2.8 |
Cash and cash equivalents | 2 321.93 | 6 452.00 | 2 919.44 | 13 149.75 | 12 138.68 |
Capital use efficiency | |||||
Trade debtors turnover (days) | |||||
Net working capital % | |||||
Credit risk | |||||
Credit rating | B | BB | B | BB | B |
Variable visualization
Roles
Companies in the same industry
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.